In this randomized trial of >18,000 patients with atrial fibrillation, apixaban was superior to warfarin for the primary outcome of stoke or embolism (1.3% vs 1.6%, 32% relative risk reduction), as well as for major bleeding (2.1% vs 3.1%), death (3.5% vs 3.9%) or hemorrhagic stroke (.24% vs .47%). As soon as FDA approved, apixaban will join dabigatran in the arsenal of oral agents safe and effective for Afib-related stroke prevention (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.